Light-Activated Prodrug Strategies for Small Molecule Drug Delivery

Introduction

A photoactivated prodrug strategy uses light to activate drug precursors which release active pharmaceutical agents thereby enhancing drug targeting while lowering systemic toxicity. The fundamental mechanism behind this approach requires photosensitizers to activate prodrugs when exposed to light of a precise wavelength to release their active components. This strategy usually involves the following steps: first, design the proactive drug through chemical modification, introduce photosensitive groups (such as platinum, iridium complexes or boric acid groups, etc.) to make it inert in vitro; then select photosensitizers that match the tumor microenvironment (such as Eosin Y, methylene blue, etc., to form ion pairs through electrostatic effects or chemical bonds to enhance targeting; then use near-infrared light or red light (630-800 nm) as the activation light source, using its tissue penetration ability to penetrate deep into the tumor area; under light triggering, the photosensitizer activates the prodrug through mechanisms such as photolysis, photosensitization or free radical generation (such as platinum IV → platinum II conversion, benzene free radical release, etc.); at the same time, precise positioning is achieved through tumor-specific marker binding (such as antibody-drug conjugate ADC) or microenvironment response (such as acidic conditions/hydrogen peroxide); ultimately, the drug action range is limited by local illumination, combined with the optimization of photosensitizer/illumination parameters, while killing tumor cells, systemic toxicity and phototoxicity are reduced. The whole process forms a closed loop: light activation not only releases active drugs, but also exacerbates tumor microenvironment changes (such as hypoxia) through ROS generation or water radiolysis, thereby promoting the secondary response of unactivated prodrugs, forming a self-enhanced therapeutic cycle.

Application Cases of Photoactivated Prodrugs in Small Molecule Drug Delivery

Figure 1. Basic schematic diagram of the various design strategies used to create small-molecule activatable "smart" phototherapeutics. (Sources: Han HH, et al. 2023)

1. Photoactivated small molecule microtubule inhibitors: A newly developed photoactivated small molecule microtubule inhibitor achieves rapid and strong polymerization inhibition by incorporating a photoremovable group like 4,5-dimethoxy-2-nitrophenyl into the drug's pharmacophore. Irradiating compound 2 with short-wavelength ultraviolet light triggers rapid and strong inhibition of microtubule polymerization and cell apoptosis while simultaneously reducing cell survival and releasing the active parent compound.
2. Photoactivated nanomedicine: By transferring the photoswitch activity from the carrier to the load and trapping the molecule in porous nanoparticles, the drug release is achieved through the photoisomerization process. This method has validated its delivery system in multiple human tumor cell lines and has potential in vivo application value, especially for skin cancer.
3. Photoactivated platinum prodrugs: Researchers have developed a photoactivated platinum prodrug, such as rhodaplatin, which significantly improves the photoconversion efficiency through intramolecular photoswitches. This prodrug accumulates in the mitochondria of cancer cells, inducing mtDNA damage, thereby overcoming drug resistance.
4. Photoactivated prodrug polymer nanoparticles: Researchers designed a photoactivated cationic polymer prodrug (PtCP) based on a tetravalent photosensitive platinum compound as a gene carrier to electrostatically compound cisplatin-resistant gene silencing small interfering RNA (siRNA) targeting cisplatin-resistant ovarian cancer. In vitro and in vivo experiments showed that the prodrug nanoplatform can quickly generate non-oxygen-dependent azide radicals, effectively enhancing the combined efficacy of chemotherapy and gene therapy.
5. Photoactivated anticancer prodrug: Researchers have developed a photosensitive anticancer prodrug that can be controllably activated by red light to release oxaliplatin. Under low-intensity red light irradiation, the prodrug can be efficiently and quickly activated to release oxaliplatin, showing stronger cytotoxicity than oxaliplatin and showing better therapeutic effects in mouse tumor models.
6. Photoactivated prodrug delivery system: The MIT research team has developed an implant that can deliver light-activated drugs. The system allows the drug to remain inactive until it reaches the target location, and then start to work when stimulated by light. This technology has been successfully tested in mice in the laboratory.

These cases demonstrate the potential of photoactivated prodrugs in the delivery of small molecule drugs, especially in cancer treatment. By precisely controlling the release time and space of the drug, these prodrugs not only improve the therapeutic effect, but also reduce side effects.

Summary

The photoactivated prodrug strategy significantly improves the targeting and safety of small molecule drugs through photosensitizer design, light source optimization and delivery system innovation. Although clinical transformation still faces challenges in penetration, device miniaturization and long-term toxicity, breakthroughs in technologies such as near-infrared photocatalysis, intramolecular switches and bioorthogonal systems have provided new tools for tumors, neurological diseases and even immunotherapy. In the future, multimodal combined therapy (such as photodynamic therapy + immunotherapy + chemotherapy) and intelligent delivery devices (such as implantable optical fibers) may become the core development direction of this field.

Small Molecule Drugs Antibodies

Small Molecule Drugs Antigen